Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Tortuosity-Powered Microfluidic Device Assesses Thrombosis

By LabMedica International staff writers
Posted on 18 Jun 2020
Accurate assessment of blood thrombosis and antithrombotic therapy is essential for the management of patients in a variety of clinical conditions, including surgery and on extracorporeal life support.

Current monitoring devices do not measure the effects of hemodynamic forces that contribute significantly to coagulation, platelet function and fibrin formation. More...
This limits the extent to which current assays can predict clotting status in patients.

Bioengineers at the Texas A&M College of Engineering (College Station, TX, USA) have developed a biomimetic microfluidic device consisting stenosed and tortuous arteriolar vessels would analyze blood clotting under flow, while requiring a small blood volume. Blood from healthy adult donors was collected upon informed consent in 3.2% sodium citrate tubes. Platelet counts were measured using a complete blood count (CBC) machine (Hemavet, Drew Scientific Inc, Miami Lakes, FL, USA). Platelets were first separated from blood via standard centrifugation methods, and they were added back to blood to achieve required concentration (count/mL).

The team reported that the microdevice mimics tortuous blood vessels and created a diseased microenvironment in which blood may rapidly clot under flow. They showed this biomimetic blood clotting device could be used to design and monitor drugs that are given to patients who suffer from clotting disorders. The team coordinated with clinicians to test the device with pediatric patients in critical care whose heart and lungs were not working properly. These patients were in need of an extracorporeal membrane oxygenation (ECMO) machine, which provides cardiac and respiratory support in exchange of oxygen and carbon dioxide.

A common complication in ECMO is blood clotting, so patients are administered anticoagulants to prevent clotting. However, ECMO machines are also known to obliterate clotting proteins and platelets, which puts anticoagulated patients in further risk of bleeding. Anticoagulated pediatric patients on ECMO are especially prone to bleeding. Current chemically based blood clotting tests are expensive, time-consuming, can be unreliable and require a skilled technician. The team’s tortuosity based microfluidic system doesn't require expensive chemicals, is quick, with results within 10-15 minutes, uses low blood sample volume and is easy to operate.

Abhishek Jain, PhD an assistant professor and senior study author, said, “We could see several applications for the device, including critical care units and military trauma care units. It can be used in detection of clotting disorders and used in precision medicine where you would want to monitor pro-thrombotic or anti-thrombotic therapies and optimize the therapeutic approach.” The study was originally published on April 1, 2020 in the journal Scientific Reports.





Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Hematology Consumables
Bioblood Devices
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.